AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10365628
Drug: Social Support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social Support Questionnaire (SSQ) administered to psychiatric patients
Trial: 10365628
Drug: Social Support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social Support Questionnaire (SSQ) administered to healthy controls
Trial: 8896396
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF; 5 micrograms/kg) plus stem cell factor (SCF; 20 micrograms/kg) after chemotherapy
Trial: 8896396
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and G-CSF alone
Trial: 7095850
Drug: 25 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 micrograms of both polysaccharides premixed in a single injection
Trial: 29347874
Drug: Hydrocortisone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (200 mg per day)
Trial: 25179916
Drug: RCT-18 (1.2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RCT-18 (1.2, 6, 18, 60, 180, 360, 540 mg)
Trial: 25179916
Drug: RCT-18 (540
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RCT-18 (540 mg)
Trial: 25179916
Drug: RCT-18 (180,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RCT-18 (180, 360, 540 mg)
Trial: 15646430
Drug: Dioctahedral smectite
RxNorm normalized name: Dioctahedral smectite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dioctahedral smectite (3 g, three sachets, administered 1 h after meals for 28 days)
Trial: 15646430
Drug: Probiotic preparation
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic preparation (Bifico 210 mg, two capsules for 28 days)
Trial: 7925518
Drug: Nisoldipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine (20 mg once daily, n = 16)
Trial: 2511299
Drug: Usual dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual dosage of lithium
Trial: 2511299
Drug: Reduced lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced lithium dosage by up to 50%
Trial: 25561281
Drug: Blood Purification
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood Purification (BP) treatment
Trial: 23116458
Drug: 3.6 mg
RxNorm normalized name: menthol 3.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6 mg MSF
Trial: 23116458
Drug: 7.2 mg
RxNorm normalized name: lysine 7.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.2 mg MSF
Trial: 23116458
Drug: 10.8 mg
RxNorm normalized name: goserelin 10.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10.8 mg MSF
Trial: 19922132
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (rhEPO) 40,000 units, administered fortnightly for 24 months
Trial: 16508590
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of olmesartan medoxomil once daily
Trial: 10661334
Drug: Chemotherapy before
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy before or after irradiation (n = 40 before, n = 15 after)
Trial: 9339690
Drug: Pramipexole (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole (up to 4.5 mg per day)
Trial: 9339690
Drug: Bromocriptine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (30 mg per day)
Trial: 8348063
Drug: Beta-carotene, 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene, 30 mg/day
Trial: 24312194
Drug: HIV‐DNA vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV‐DNA vaccine in addition to ongoing antiretroviral treatment (ART) (Group B)
Trial: 24312194
Drug: Ongoing antiretroviral
RxNorm normalized name: Ongo-Fin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ongoing antiretroviral treatment (ART) (Group A)
Trial: 18432528
Drug: High-dose polyestradiol
RxNorm normalized name: POLYESTRADIOL
DrugBank: Polyestradiol phosphate (DB09369)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose polyestradiol phosphate (PEP; Estradurin) 240 mg i.m. twice a month for 2 months and thereafter monthly
Trial: 18432528
Drug: Combined androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined androgen deprivation (CAD) with flutamide (Eulexin) 250 mg t.i.d. and triptorelin (Decapeptyl) 3.75 mg i.m. per month or bilateral orchidectomy
Trial: 12854267
Drug: Calcium ascorbate
RxNorm normalized name: Calcium Ascorbate
DrugBank: Calcium ascorbate (DB14483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium ascorbate (1 gram daily for 14 +/- 3 days)
Trial: 12854267
Drug: Placebo (identically
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identically looking tablets)
Trial: 8561070
Drug: n‐3 polyunsaturated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3 polyunsaturated fatty acid‐rich fish oil supplement for 21 days
Trial: 8561070
Drug: n‐3 polyunsaturated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3 polyunsaturated fatty acid‐rich fish oil supplement with interferon‐gamma incubation
Trial: 1907839
Drug: Pravastatin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin with propranolol (40 mg twice daily)
Trial: 1907839
Drug: Lovastatin with
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lovastatin with propranolol (40 mg twice daily)
Trial: 28077530
Drug: Maize-derived HES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maize-derived HES solution
Trial: 28077530
Drug: Potato-derived HES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potato-derived HES solution
Trial: 19008724
Drug: moxonidine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: moxonidine (0.3 mg twice daily)
Trial: 19008724
Drug: atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atenolol (50 mg once daily)
Trial: 15953083
Drug: Moisturizing cream
RxNorm normalized name: MOISTURIZING CREAM
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moisturizing cream applied twice daily for 6 weeks
Trial: 3909132
Drug: i.m. morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.m. morphine (4, 8 and 16 mg)
Trial: 30834812
Drug: Unilateral hybrid
RxNorm normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral hybrid therapy (UHT; unilateral robot‐assisted therapy + modified constraint‐induced movement therapy)
Trial: 30834812
Drug: Bilateral hybrid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral hybrid therapy (BHT; bilateral robot‐assisted therapy + bilateral arm training)
Trial: 30834812
Drug: Robot therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot therapy (RT)
Trial: 29423521
Drug: Sym004, 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sym004, 12 mg/kg/wk (arm A)
Trial: 29423521
Drug: Sym004, 9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sym004, 9 mg/kg loading dose followed by 6 mg/kg/wk (arm B)
Trial: 29423521
Drug: Investigator's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator's choice of treatment (arm C)
Trial: 26813548
Drug: β-blocker (BB)
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: β-blocker (BB) treatment (any molecule and any dose)
Trial: 26813548
Drug: Non-BB treatment
RxNorm normalized name: Dream Pure BB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-BB treatment
Trial: 25100236
Drug: rosuvastatin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin (5 or 2.5 mg/day)
Trial: 22883585
Drug: Heparin gelatin
RxNorm normalized name: Gelatin
DrugBank: Gelatin (DB11242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin gelatin sponge stickers
Trial: 21059972
Drug: Twice-a-week supervised
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-a-week supervised aerobic and resistance training plus structured exercise counseling
Trial: 9095400
Drug: Remacemide hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Remacemide (DB06458)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remacemide hydrochloride 300 mg twice daily
Trial: 27680049
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy associated with Essential Fatty Acids
Trial: 20189659
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (1.5mg/kg of 2% lidocaine)
Trial: 18925883
Drug: Cumulative received
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative received vaccine doses
Trial: 16687966
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with amlodipine besylate/benazepril hydrochloride 5/20 mg
Trial: 16687966
Drug: Benazepril hydrochloride
RxNorm normalized name: Benazepril Hydrochloride
DrugBank: Benazepril (DB00542)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benazepril hydrochloride 20 mg
Trial: 11075844
Drug: Almotriptan (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almotriptan (both doses)
Trial: 22722501
Drug: Paliperidone ER
RxNorm normalized name: Paliperidone ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paliperidone ER (6-9 mg/d)
Trial: 22722501
Drug: Oral Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Olanzapine (10-15 mg/d)
Trial: 19720897
Drug: Pemetrexed-carboplatin (pemetrexed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed-carboplatin (pemetrexed 500 mg/m² on day 1; carboplatin AUC 5 on day 1)
Trial: 19720897
Drug: Etoposide-carboplatin (etoposide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoposide-carboplatin (etoposide 100 mg/m² on days 1-3; carboplatin AUC 5 on day 1)
Trial: 11919238
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy (chemotherapy, hormonal therapy, or both) for node-positive disease
Trial: 11919238
Drug: Combined multidrug
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined multidrug chemotherapy plus tamoxifen for node-positive disease
Trial: 11919238
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy for node-negative disease
Trial: 11919238
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy for node-negative tumors > or = 1 cm diagnosed in 1995
Trial: 11919238
Drug: Both tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both tamoxifen and combination chemotherapy for node-negative tumors > or = 1 cm diagnosed in 1995
Trial: 11919238
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy for node-negative tumors > or = 1 cm diagnosed in 1987
Trial: 11919238
Drug: Both tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both tamoxifen and combination chemotherapy for node-negative tumors > or = 1 cm diagnosed in 1987
Trial: 9598218
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of fenfluramine (FEN)
Trial: 8185343
Drug: FUT-187 (sepimostat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FUT-187 (sepimostat mesilate) 300 mg/day
Trial: 8185343
Drug: FUT-187 (sepimostat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FUT-187 (sepimostat mesilate) 400 mg/day
Trial: 2820312
Drug: Vindesine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vindesine (3 mg/m2 X 3) plus cisplatin (80‐120 mg/m2)
Trial: 2820312
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (8 mg/m2) plus vindesine (2 mg/m2 X 3) plus cisplatin (80‐120 mg/m2)
Trial: 30001547
Drug: Phonological Reading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phonological Reading and Writing Remediation Program (24 cumulative sessions, twice a week, 30 min each)
Trial: 22495941
Drug: Escitalopram monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram monotherapy (escitalopram and placebo)
Trial: 22495941
Drug: Antidepressant combination
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant combination (venlafaxine-XR and mirtazapine or escitalopram and bupropion-SR)
Trial: 22495941
Drug: MDD with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDD with concurrent SUD
Trial: 22495941
Drug: MDD without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MDD without concurrent SUD
Trial: 12810991
Drug: Iontophoresis with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iontophoresis with alternating current (AC) combined with anticholinergic drugs
Trial: 10380089
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone (3 x 500 microg)
Trial: 10380089
Drug: Systemic dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Systemic dexamethasone (0.5 mg/kg/day)
Trial: 7483814
Drug: Recombinant staphylokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant staphylokinase (10 mg intravenous infusion over 30 min)
Trial: 1682544
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg orally per day for 10 days
Trial: 1682544
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg orally per day for 20 or 30 days
Trial: 1682544
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg orally per day
Trial: 1682544
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg orally per day for at least 20 days
Trial: 31997084
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg plus 300 mg green tea extract
Trial: 31997084
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg plus 600 mg green tea extract
Trial: 31997084
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg alone
Trial: 30471953
Drug: DTaP-IPV-HB-PRP-T co-administered
RxNorm normalized name: Hib (PRP-T)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP-IPV-HB-PRP-T co-administered with MenACWY-TT vaccine (Group A; n=104)
Trial: 30471953
Drug: DTaP-IPV-HB-PRP-T vaccine
RxNorm normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP-IPV-HB-PRP-T vaccine alone (Group B; n=105)
Trial: 30471953
Drug: MenACWY-TT vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY-TT vaccine alone (Group C; n=103)
Trial: 15257733
Drug: Ultrasonic instrumentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasonic instrumentation + application of 8.5% w/w doxycycline gel (Atridox)
Trial: 9193198
Drug: L-745,870 (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-745,870 (15 mg/d)
Trial: 9193198
Drug: L-745,870
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-745,870
Trial: 1539847
Drug: morphine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine (0.1 mg.kg‐1, iv)
Trial: 1539847
Drug: ketorolac (0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketorolac (0.9 mg.kg‐1, iv)
Trial: 18278698
Drug: Chemotherapy (specifics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (specifics not provided)
Trial: 18278698
Drug: Pharmacogenetics and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacogenetics and pharmacogenomics (individualisation of therapy)
Trial: 12618256
Drug: 400 microg
RxNorm normalized name: Fentanyl 400 microgram buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 microg sublingual misoprostol 3 h prior to vacuum aspiration (VA)
Trial: 8608073
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml 0.5% plain bupivacaine
Trial: 8608073
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml 0.75% hyperbaric bupivacaine premixed in 8.25% glucose
Trial: 2669036
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose total body irradiation (STBI) - 10 Gy at a 4.5 cGy/min dose rate, 8 Gy to the lungs
Trial: 23362
Drug: 1% selenium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% selenium disulfid suspension
Trial: 27932871
Drug: FFR-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FFR-guided therapy
Trial: 27932871
Drug: Angiography-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiography-guided therapy
Trial: 20975109
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein and leucine supplementation (19.7 g of whey protein and 6.2 g of leucine)
Trial: 18552703
Drug: Guanfacine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanfacine (3 mg/day maximum dose)
Trial: 7481023
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: Initial dose of 8 ml bupivacaine 0.25% (20 mg) with epinephrine 1/200,000 and 50 micrograms fentanyl followed by continuous infusion of 8 ml/h bupivacaine 0.125% (10 mg/h) with epinephrine 1/400,000
Trial: 7481023
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: Initial dose of 10 ml bupivacaine 0.125% (12.5 mg) with epinephrine 1/400,000 and 50 micrograms fentanyl followed by continuous infusion of 12 ml/h bupivacaine 0.0625% (7.5 mg/h) with epinephrine 1/800,000 and 12 micrograms/h fentanyl
Trial: 7481023
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: Initial dose same as group A, but maintenance through a patient‐controlled (PCA) system with 5 ml bupivacaine 0.25% (12.5 mg) and epinephrine 1/200,000 set for a minimum interval of 1 h
Trial: 2196631
Drug: Nortriptyline (NT)
DrugBank: Nortriptyline (DB00540)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nortriptyline (NT) at a plasma level of 80 +/- 20 ng/ml, monitored weekly over 8 weeks.
Trial: 22419
Drug: Nabilone (2-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabilone (2-mg single doses)
Trial: 22419
Drug: Diazepam (5-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (5-mg single doses)
Trial: 30999915
Drug: Artesunate-mefloquine (ASMQ)
RxNorm normalized name: artesunate and mefloquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate-mefloquine (ASMQ) fixed dose combination, 25/55 mg AS/MQ administered once a day for 3 days
Trial: 29880750
Drug: Glutamine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine (30 g) with low-nutrient drink (beef soup; 18 kcal)
Trial: 29880750
Drug: Glutamine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine (30 g) with high-nutrient drink (75 g dextrose; 255 kcal)
Trial: 27521811
Drug: Abstinence Reinforcement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abstinence Reinforcement Therapy (ART) which includes cognitive-behavioral telephone counseling (TC), telemedicine clinic for nicotine replacement (NRT), and mobile contingency management (mCM)
Trial: 25490675
Drug: H1/IC31 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H1/IC31 vaccine
Trial: 17686832
Drug: Salba (37
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salba (37 ± 4 g/day)
Trial: 15596419
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate (TU, 80 mg bid)
Trial: 11983659
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg x kg(‐1) ketorolac (maximum of 15 mg) six hourly postoperatively for 36 hr
Trial: 11983659
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg x kg(‐1) ketorolac
Trial: 9818634
Drug: Citalopram 10
RxNorm normalized name: citalopram 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram 10 or 15 mg/day
Trial: 4785
Drug: Intranasal beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal beclomethasone dipropionate (50 micrograms in each nostril four times a day)
Trial: 4785
Drug: Placebo aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo aerosol preparation identical in appearance
Trial: 31358032
Drug: PCT-based algorithm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCT-based algorithm to guide antibiotic use